IQVIA Laboratories Discovery UK Ltd carries an average payment time of 51 days, sitting just inside the 31–60 day bracket that accounts for the largest single share of payments at 45%. The 43% paid within 30 days indicates a meaningful portion of invoices are settled promptly, but this is offset by 12% of payments extending beyond 60 days, suggesting persistent delays on a notable minority of transactions. The overall payment profile points to a mid-range payer with no strong trend toward early settlement.
With 29% of payments classified as late, nearly one in three invoices is not honoured within agreed terms, representing a meaningful reliability concern for suppliers managing cash flow. The spread across all three time bands — 43%, 45%, and 12% — indicates inconsistent payment behaviour rather than a predictable cycle, making it difficult to forecast exactly when funds will arrive. This variability introduces working capital risk, particularly for suppliers with tighter liquidity requirements or shorter standard payment terms.
IQVIA Laboratories Discovery UK Ltd presents a moderate-to-elevated payment risk profile, suitable for engagement but with clear conditions warranted. Suppliers should consider negotiating shorter contractual payment terms (e.g., net 30) to account for the 51-day average, and build in buffer time when forecasting cash receipts. Implementing proactive invoice chasing processes and potentially requiring partial upfront payment or credit insurance would be prudent risk mitigation steps before extending significant credit exposure.
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 29 Jun 2025 - 27 Dec 2025 | 23 Jan 2026 | 41 | 50% | 46% | 4% | 28% |
| 29 Dec 2024 - 28 Jun 2025 | 23 Jan 2026 | 48 | 31% | 54% | 15% | 36% |
| 30 Jun 2024 - 28 Dec 2024 | 23 Jan 2026 | 37 | 48% | 49% | 3% | 20% |
| 31 Dec 2023 - 29 Jun 2024 | 23 Jan 2026 | 48 | 43% | 48% | 9% | 22% |
| 01 Jan 2023 - 24 Jun 2023 | 29 Jan 2026 | 51 | 43% | 45% | 12% | 29% |
This information is as reported by the business, and responses are in their own words.
Standard payment terms
Net 60 days
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
No additional information
Maximum contractual payment period agreed
90
All payments are scheduled in line with agreed vendor payment terms. Initial payment queries should be addressed to Accounts Payable, and payment term disputes should be addressed to Procurement.
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
IQVIA LABORATORIES DISCOVERY UK LTD is a private limited company operating within the pharmaceutical and life sciences sector. The company forms part of the IQVIA group, a global organisation specialising in laboratory discovery services and research solutions.
The company is registered in England and Wales under company number 04622227 and was incorporated on 19 December 2002. Its registered office is located at 3 Forbury Place, 23 Forbury Road, Reading, RG1 3JH, placing it within the South East region of the United Kingdom.
Companies of this nature within the UK life sciences sector provide specialist laboratory and drug discovery services, supporting pharmaceutical and biotechnology clients through the early stages of research and development. These services typically encompass compound screening, medicinal chemistry, and analytical laboratory support designed to accelerate the identification and development of new therapeutic candidates.
With over two decades of operation in the UK market, IQVIA LABORATORIES DISCOVERY UK LTD represents an established presence within the British life sciences and contract research organisation landscape, serving clients across the pharmaceutical and biotech industries.